Recent Quotes (30 days)

You have no recent quotes
chg | %

AstraZeneca plc news

   Watch this stock
Showing stories 1 - 10 of about 163   

Articles published

AZN 4,950.50 -24.00 (-0.48%)
price chart
AstraZeneca plc 15.4% Potential Decrease Indicated by JP Morgan Cazenove
AstraZeneca plc with EPIC/TICKER LON:AZN had its stock rating noted as 'Reiterates' with the recommendation being set at 'NEUTRAL' today by analysts at JP Morgan Cazenove.
AstraZeneca plc's (AZN) “Neutral” Rating Reaffirmed at JPMorgan Chase ...  The Cerbat Gem
AstraZeneca plc (AZN) Stock Rating Reaffirmed by BNP Paribas  BNB Daily (blog)
AstraZeneca plc 22% Potential Upside Indicated by Barclays Capital
AstraZeneca plc with EPIC/TICKER LON:AZN had its stock rating noted as 'Reiterates' with the recommendation being set at 'OVERWEIGHT' this morning by analysts at Barclays Capital.
Stock On the Run: AstraZeneca PLC (AZN)  HugoPress
Stock Overbuying in Action: AstraZeneca plc (ADR (NYSE:AZN)  Post Registrar
Form 6-K ASTRAZENECA PLC For: Mar 27
AstraZeneca PLC (the Company) announces that, on 24 March 2017, certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) were each granted awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) or of ...
New Lung Cancer Drug From AstraZeneca is Approved in China
AstraZeneca Plc said it had a key lung cancer drug approved in China, opening up a new market for the therapy and allowing U.K.
AstraZeneca plc (ADR) Receives Key Lung Cancer Drug Approval In China  StockNews.com (blog)
Market Risers: Ashtead Group plc, Associated British Foods plc, AstraZeneca ...
Shares in Ashtead Group plc with company EPIC: LON:AHT has increased 2.18% or 35 points during today's session so far. Market buyers have stayed positive during the session.
Analyst Activity – Leerink Swann Reiterates Outperform on AstraZeneca plc ...  Market Exclusive
AstraZeneca PLC performed Very Well with a change of 2.01% in the Last Trade  Free Observer
AstraZeneca plc (AZN) – Filing Season Finds: Thursday, March 9
Analyst Cody Fincher found an unusual item yesterday in Astrazeneca PLC's (AZN) 20-F (the international equivalent of a 10-K).
Is AstraZeneca Plc (ADR) (NYSE:AZN) a Buy Despite of Patent Worries and Weak ...  Library For Smart Investors
AstraZeneca plc (ADR) (NYSE:AZN) Rejected Drugs To Be Reconsidered  Market Exclusive
AstraZeneca plc: AstraZeneca and Circassia enter strategic collaboration in ...
AstraZeneca today announced it has entered a strategic collaboration with Circassia Pharmaceuticals plc, a respiratory biopharmaceutical company, for the development and commercialisation of Tudorza and Duaklir* in the US.
Woodford-Backed Biopharma Stock Circassia Surges on Astra Pact  Bloomberg
Astra collaboration breathes new life into Circassia  Proactive Investors UK
Here's What Just Happened With AstraZeneca plc (ADR) (NYSE:AZN), TESARO Inc ...
It's been a big week for PARP inhibitors. AstraZeneca plc (ADR) (NYSE:AZN) just put out data from a phase 3 investigation of its lead PARP asset Lynparza, and the data came out as impressive.
AstraZeneca's Cancer Drug Lynparza Positive in Phase III  Yahoo Finance
Stock Market Movers- AstraZeneca plc (ADR) (NYSE:AZN), Sandstorm Gold Ltd ...  Wall Street Times (press release)
AstraZeneca Stock Rising in '17: What's Working in its Favor?
In addition to acquisitions, the company is pursuing co-development deals with companies like Nektar Therapeutics NKTR, Eli Lilly & Company LLY, Ionis, Allergan plc AGN, Merck and Valeant to boost its pipeline. AstraZeneca has been making significant ...
Barclays Capital analysts "resoundingly positive" on pharma stocks ...
The number crunchers in the research department at Barclays Capital have initiated coverage of the EU pharma sector with a “resoundingly positive view”.